

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

IMIQUIMOD

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
IMIQUIMOD	ZYCLARA		28216	GPI-14	
			31436	(90773040003715)	
			32958	(90773040003710)	

GUIDELINES FOR USE

- 1. Does the patient have a diagnosis of actinic keratosis (AK) of the full face or balding scalp and meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient is immunocompetent
 - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

If yes, approve the requested strength for 4 months by GPID or GPI-14 with the following quantity limits:

- 3.75% packet: #28 packets per 28 days.
- 2.5% or 3.75% pump: #7.5g per 28 days.

If no, continue to #2.

- 2. Does the patient have a diagnosis of external genital or perianal warts and meet **ALL** of the following criteria?
 - The patient is 12 years of age or older
 - The patient had a trial of or contraindication to generic imiguimod 5% topical cream

If yes, approve the requested strength for 2 months by GPID or GPI-14 with the following quantity limits:

- 3.75% packet: #28 packets per 28 days.
- 2.5% or 3.75% pump: #7.5g per 28 days.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **IMIQUIMOD (Zyclara)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Actinic keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the full face or balding scalp
 - 2. External genital or perianal (around the anus) warts

(Denial text continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/19/2023 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

IMIQUIMOD

GUIDELINES FOR USE (CONTINUED)

- B. If you have actinic keratosis of the full face or balding scalp, approval also requires:
 - 1. You are 18 years of age or older
 - 2. You are immunocompetent (healthy immune system)
 - 3. You had a trial of TWO generic topical agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)
- C. If you have external genital or perianal warts, approval also requires:
 - 1. You are 12 years of age or older
 - 2. You have tried or have a contraindication (harmful for) to generic imiquimod 5% topical cream

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Zyclara.

REFERENCES

• Zyclara [Prescribing Information]. Bridgewater, NJ: Bausch Health US, LLC; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 08/97

Commercial Effective: 06/12/23 Client Approval: 05/23 P&T Approval: 04/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/19/2023 Page 2 of 2